Found 92 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The present confirmatory phase 3 trial will be conducted to further investigate the efficacy and safety of molgramostim in subjects with aPAP. Investigating how molgramostim improves lung pathology, pathophysiology, and health status in subjects with aPAP in a dose- frequency dependent fashion.
Prospective, randomized, parallel group, double-blind, concurrently controlled, multi-center clinical trial following patients to 2 years to assess the safety and effectiveness the treatment of the symptoms of chronic bronchitis in adult COPD patients with moderate to severe chronic bronchitis.
This is a double-blind, placebo controlled study to assess the safety and efficacy of BI1015550 on patients with IPF. It is a phase 3 study and will including physical exams, a CT, questionnaires, safety lab samples, lung function testing, and ECGs.
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …
Parallel, Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial The primary objective is to evaluate the safety of oral LT3 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) The secondary objective is to evaluate the feasibility and preliminary efficacy outcomes of oral LT3 therapy …
Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability and PK of vupanorsen administered subcutaneously at various doses and regimens with patients with dyslipidemia. Patients will participate for approximately 10 months, and will have blood draws, physical exams, ECGs, and MRIs.
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour …
this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 mg and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with TRD, as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from …
